Metabotropic Glutamate Receptor (MRG) Market

Executive Summary

Metabotropic Glutamate Receptor (MRG) Market was valued at US $2.25 million in 2021 and is projected to grow at 12.43% CAGR over the forecast period to reach US $4.54 million by 2027. Metabotropic Glutamate Receptor (MRG) Market represented US $0.47 million opportunity over 2019-2021 and estimated to create US $2.29 million opportunity in 2027 over 2021.

Metabotropic Glutamate Receptor (MRG) from Consainsights analyses the Metabotropic Glutamate Receptor (MRG) Market in the Life Sciences industry over the forecast period to 2027.

Metabotropic Glutamate Receptor (MRG) research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Metabotropic Glutamate Receptor (MRG) segmentation includes Product Type, Application and Geography.

Based on the Product Type, the Metabotropic Glutamate Receptor (MRG) analysis covers MGLUR2, MGLUR4, MGLUR5.

In Product Type segment, MGLUR2 segment has highest cagr growth of 10.98%.

Based on the Application, the Metabotropic Glutamate Receptor (MRG) analysis covers ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD), ALZHEIMER’S DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD).

In Application segment, ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) segment has highest cagr growth of 10.98%.

Based on the region, the Metabotropic Glutamate Receptor (MRG) analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include ADDEX THERAPEUTICS LTD, DOMAIN THERAPEUTICS SA, MEDGENICS, PREXTON THERAPEUTICS SA, TAISHO PHARMACEUTICAL HOLDING and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product Type

Introduction

In 2021, MGLUR2 segment has the highest revenue of US $1.73 million and is expected to grow at CAGR of 10.98% by 2027 MGLUR2 segment has highest cagr growth of 10.98%.

MGLUR2

MGLUR2 segment was valued at US $1.37 million in 2019 and is projected to grow at 10.98% CAGR over the forecast period to reach US $3.50 million by 2027. MGLUR2 segment represented US $0.36 million opportunity over 2019-2021 and estimated to create US $1.77 million opportunity in 2027 over 2021.

MGLUR4

MGLUR4 segment was valued at US $0.40 million in 2019 and is projected to grow at 10.98% CAGR over the forecast period to reach US $1.03 million by 2027. MGLUR4 segment represented US $0.11 million opportunity over 2019-2021 and estimated to create US $0.52 million opportunity in 2027 over 2021.

MGLUR5

MGLUR5 segment was valued at US $0.00 million in 2019 and is projected to grow at 10.98% CAGR over the forecast period to reach US $0.01 million by 2027. MGLUR5 segment represented US $0.00 million opportunity over 2019-2021 and estimated to create US $0.00 million opportunity in 2027 over 2021.

Application

Introduction

In 2021, ALZHEIMER’S DISEASE segment has the highest revenue of US $0.90 million and is expected to grow at CAGR of 10.98% by 2027 ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) segment has highest cagr growth of 10.98%.

ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) segment was valued at US $0.58 million in 2019 and is projected to grow at 10.98% CAGR over the forecast period to reach US $1.48 million by 2027. ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) segment represented US $0.15 million opportunity over 2019-2021 and estimated to create US $0.75 million opportunity in 2027 over 2021.

ALZHEIMER’S DISEASE

ALZHEIMER’S DISEASE segment was valued at US $0.72 million in 2019 and is projected to grow at 10.98% CAGR over the forecast period to reach US $1.83 million by 2027. ALZHEIMER’S DISEASE segment represented US $0.19 million opportunity over 2019-2021 and estimated to create US $0.92 million opportunity in 2027 over 2021.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) segment was valued at US $0.48 million in 2019 and is projected to grow at 10.98% CAGR over the forecast period to reach US $1.23 million by 2027. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) segment represented US $0.13 million opportunity over 2019-2021 and estimated to create US $0.62 million opportunity in 2027 over 2021.